We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

FGFR

Fibroblast growth factor receptor (FGFR) inhibitors act on FGFR1 to FGFR4, four receptor tyrosine kinases. FGFR signaling controls cell proliferation, migration and differentiation in development and angiogenesis. Amplifications, activating mutations and gene fusions of FGFR genes have been found in many tumor types. PD173074 was crystallized with the FGFR1 kinase domain in 1998, which showed how it occupies the adenosine triphosphate (ATP) pocket. Infigratinib and fexagratinib are FGFR-focused inhibitors used to study cells that depend on FGFR signaling. Nintedanib and pazopanib HCl inhibit FGFR together with vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Kinases outside the FGFR family are covered by sibling categories such as VEGFR and PDGFR.

1 Item

  • FGL peptide
    Cat. No.
    A33497
    CAS No.
    499993-62-3

    FGL peptide

    FGL peptide is a fibroblast growth factor receptor (FGFR) activator that effectively penetrates the blood-brain barrier. It initiates NCAM-FGFR and FGFR1 signaling pathways, which modulate the expression of genes involved in apoptosis, signal transduction, and metabolic regulation. FGL peptide is primarily utilized in research focused on traumatic brain injury, offering insights into its underlying molecular mechanisms and potential therapeutic targets.

    In stock View Details
    5 mg
    $85.00
    10 mg
    $140.00
    All 5 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...